Safety Study of Quadrivalent Influenza Virus Vaccine in Healthy People Aged 3 Years and Older

Quadrivalent Influenza Virus Vaccine Clinical Trial

Status Completed

Clinical Trial Summary

This study evaluates the safety of Quadrivalent Influenza Virus Vaccine in Healthy People Aged years 3 to 60.40 Subjects will be equally divided into 2 groups,including 3-17 years old and 18-60 years old.Adult group first receive one dose of Quadrivalent Influenza Virus Vaccine.Then minors group also receive one dose of Quadrivalent Influenza Virus Vaccine after 7 days.

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza, Human
• Quadrivalent Influenza Virus Vaccine

• NCT number: NCT02708173
• Study type: Interventional
• Source: Beijing Chaoyang District Centre for Disease Control and Prevention
• Status: Completed
• Phase: Phase 1
• Start date: March 2016
• Completion date: June 2016